Across TCGA pan-cancer cohorts, HSPA14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSPA14 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSPA14 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HSPA14 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where HSPA14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	IV	0.490	0.973	.024	9	view →
LUAD	DFS	Quartile	All	0.506	1.000	.019	4	view →
LSCC	OS	Median	III,IV	0.451	0.840	.015	4	view →
GBM	DFS	Tertile	All	0.472	0.216	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HSPA14 tumor-vs-normal RNA expression · all HSPA14 data types